7/19/18: “Our focus will be on delivering innovation that is life-changing—for patients, customers, employees, communities and other stakeholders—and we will grow our business for long-term success,” said Mr. Westgate. “We are very excited about pursuing new product development road maps that will position us to meet the diverse needs of our customers in the markets we will serve. Customer satisfaction, continuous innovation and operational excellence will be fundamental to our culture and we are committed to being the very best at what we do.”
7/11/18: Jill Smith, CEO of Allied Minds commented “We are delighted to make this investment in additional talent at Precision Biopsy. We believe Adam’s direct experience in leading successful FDA outcomes, as well as in marketing and quality control, will be invaluable to the Precision Biopsy team.”
7/2/18: Andrew Sandham, Executive Chairman of PredictImmune commented: “Paul has more than 25 years of global leadership experience in disruptive life science and diagnostics companies and has a proven track record in transforming organisations while driving commercial success and growth. I’m delighted to welcome Paul to the team and look forward to working with him to bring our ground-breaking products to market.”
6/27/18: "Throughout my career, I've been heavily involved in the development and sales of orthopedic implants. While I enjoyed providing hardware implants to surgeons, what really motivates me is providing biologic solutions to meet patient needs," said Yamada.